

Review

Automated Systems Based on Wearable Sensors for the Management of Parkinson's Disease at Home: A Systematic Review

AU1 Erika Rovini, MD,¹ Carlo Maremmani, PhD,²
and Filippo Cavallo, PhD¹

¹The BioRobotics Institute, Scuola Superiore Sant'Anna,
Pontedera (PI), Italy.

²U.O. Neurologia, Ospedale delle Apuane (AUSL Toscana
Nord Ovest), Massa (MS), Italy.

Abstract

Background: Parkinson's disease is a common neurodegenerative pathology that significantly influences quality of life (QoL) of people affected. The increasing interest and development in telemedicine services and internet of things technologies aim to implement automated smart systems for remote assistance of patients. The wide variability of Parkinson's disease in the clinical expression, as well as in the symptom progression, seems to address the patients' care toward a personalized therapy.

Objectives: This review addresses automated systems based on wearable/portable devices for the remote treatment and management of Parkinson's disease. The idea is to obtain an overview of the telehealth and automated systems currently developed to address the impairments due to the pathology to allow clinicians to improve the quality of care for Parkinson's disease with benefits for patients in QoL.

Data Sources: The research was conducted within three databases: IEEE Xplore®, Web of Science®, and PubMed Central®, between January 2008 and September 2017.

Study Eligibility Criteria: Accurate exclusion criteria and selection strategy were applied to screen the 173 articles found.

Results: Ultimately, 55 articles were fully evaluated and included in this review. Divided into three categories, they were automated systems actually tested at home, implemented mobile applications for Parkinson's disease assessment, or described a telehealth system architecture.

Conclusion: This review would provide an exhaustive overview of wearable systems for the remote management and automated assessment of Parkinson's disease, taking into account the reliability and acceptability of the implemented technologies.

Keywords: eHealth, IoT, m-Health, Parkinson's Disease, telemedicine, telemonitoring, wearable sensors

Introduction

The increasing aging of population is resulting in a wide prevalence of chronic diseases such as neurodegenerative disorders, which require long-term high-cost treatments.¹ A plan to develop strategies able to reduce healthcare costs for age-related pathologies is an important challenge for the future.^{2,3} In this scenario, Parkinson's disease (PD) is a neurodegenerative illness that affects millions of people worldwide, and its incidence is growing.⁴ PD is caused by a critical loss of dopamine in the forebrain, which results in typical cardinal motor symptoms such as tremor, postural instability, muscular rigidity, and bradykinesia/hypokinesia.⁵ In addition, common nonmotor symptoms such as autonomic dysfunctions, sleep disturbances, and olfactory symptoms are critical factors that degrade the quality of life (QoL) of PD patients⁶ and make the pathology severely disabling, both physically and socially.^{7,8}

The long-term development of the disease, expression of symptomatic complications (e.g., motor fluctuations) during specific times of day, long waiting lists, and traveling costs (particularly for people who live in rural areas) are just a few reasons that support the need to move Parkinson's care into the home and to develop new care models.⁹

The wide variability in clinical expression, as well as in progression of somatic symptoms,¹⁰ makes the pathology difficult to adequately identify and treat.¹¹ Particularly, as the pathology onset appears unilaterally, with specific impairments, and it develops differently among patients,¹² it makes sense that a personalized and adapted therapy should be administered based on the individual needs of PD patients. This approach would enable optimal care and would treat the predominant symptoms.¹³ The approach would also meet the principles of the novel precision medicine concept for healthcare systems,¹⁴ which aim to provide the best available care for each subject. In particular, precision medicine is expected to integrate the best evidence-based knowledge in different fields, including molecular imaging, deep brain

ROVINI ET AL.

stimulation, and wearable sensors, to identify the optimal solution for the treatment and management of PD patients.¹⁵ Personalized strategies are also important to support patients' engagement in their care path, making them active in their own health.¹⁶

Recently, advances in wearable sensors, information, and communication technologies, as well as data mining, are promoting the design and the implementation of e-Health systems that allow to provide novel therapeutic and monitoring solutions for PD patients.¹⁷ These systems aim to maximize the efficiency of healthcare, enhancing its quality without increasing costs. This is accomplished through augmented contacts between patients and clinicians and sharing information between the different stakeholders. These systems also promote the empowerment of patients to actively manage their health and to adopt healthy behaviors.¹⁸ In the same vein, internet of things (IoT) systems for healthcare are emerging.¹⁹ They can allow the collection of huge amounts of patients' data through wearable sensors that are connected to a medical database through mobile devices. These data are analyzed by intelligent algorithms to obtain useful information for discriminating relevant health conditions, adjusting therapy, monitoring disease progression, and supporting both clinicians and patients in decision-making.

This review article aims to provide a wide overview of the telehealth and automated systems currently developed to address the impairments caused by PD to allow the clinicians to improve the quality of care for the pathology and provide relative benefits for patients in QoL. In particular, this article provides a review of the typologies of smart systems that were investigated and implemented for PD management in the last decade and focuses both on the kind of technology used and the system performance. Such systems are organized into three different categories on the basis of their level of development. Indeed, some works presented technologies able to provide automatic assessment of one or more specific impairments in PD, and they were tested in the actual home environment. Alternatively, other studies focused on the development of mobile health applications for remote automated PD management. Finally, several articles described the architecture of a telemedicine system for the provision of a remote healthcare service for PD patients. For each category, the existing systems that emerged from the review process were investigated, analyzed, and discussed.

Materials and Methods

DATA SOURCES

An electronic database search was performed on September 15, 2017 using IEEE Xplore[®], Web of Science[®], and PubMed

Central[®] to identify articles concerning the use of wearable sensors for automated and remote management of Parkinson's disease. According to the PRISMA statement,²⁰ an additional manual search was performed (e.g., through citations of articles included in this review), but no further articles were relevant for inclusion in this review article.

SEARCH TERMS

Specifically, the terms and keywords used for the literature research were ("Parkinson") AND ("wearable" OR "inertial" OR "accelerometer" OR "acceleration" OR "gyroscope" OR "EMG" OR "EEG" OR "ECG" OR "GSR" OR "clothes") AND ("Telemedicine" OR "Telehealth" OR "Telecare" OR "Tele-monitoring" OR "mhealth" OR "ehealth" OR "M-Health" Or "E-Health" OR "Mobile Health" OR "Home Monitoring" OR "IoT" OR "Internet of Things") located within title and/or abstract and/or keywords.

STUDY SELECTION PROCESS

Only original full-text articles published in English, between January 2008 and September 2017, which discussed the use of wearable/portable sensors for automated remote PD assessment and management, were included in this review. First, duplicated references were manually identified and excluded. Then, during the screening procedure, items were excluded if: (1) they were an abstract, a letter, a review article, or a chapter from a book or (2) they were not written in the English language. Each author independently screened the articles that were excluded with reason if: (1) they did not use any type of wearable/portable sensors; (2) they did not manage Parkinson's Disease; (3) they did not appear appropriate for this review after the reading of title and abstract; or (4) they were not full access. In addition, (5) if multiple articles written by the same author had similar content, articles published in journals were selected instead of articles presented at conferences. Furthermore, (6) if multiple articles written by the same author with similar content were presented at conferences, the most recent article was selected. Disagreements about the inclusion/exclusion and classification of the articles were solved through meetings and discussions among the authors.

Finally, the selected articles, fully evaluated and included in this review, were classified into three groups based on whether (1) they implemented devices for automatic assessment of PD symptoms or impairments (e.g., freezing of gait [FOG], tremor) and they were tested in the actual home environment; (2) they developed m-health applications on smartphone/tablet for PD; or (3) they designed a telemedicine service, describing its architecture.

WEARABLE SENSORS FOR PARKINSON'S DISEASE AT HOME

DATA ABSTRACTION

Data were abstracted from each selected article, as reported in T1 – T3 *Tables 1–3*. For the first 2 categories evidenced the technological solutions used, the experimental aspects, and the performed analysis. In particular, for the technology, the typology of the sensors, their placement over the body, and the sampling frequency were reported. About the experimental sessions, the designed protocol adopted and the subjects involved according to their pathology and their health status were described. Furthermore, the last three columns of the *Tables 1–3* synthetized the extracted features, the applied statistical methods, the implemented classifiers, and the main findings for each work. Differently, for the third category, the focus was on the technology used, the symptom addressed, the architecture and performance of the telehealth system, and the preventative measures adopted in terms of privacy and secure transmission of data.

Results

APPLICATION OVERVIEW

Obtained in the research were 173 articles: 62 references were retrieved from IEEE Xplore, 43 references were obtained from Web of Science, and 68 references were taken from PubMed Central. After removing the duplicated items, 106 references were fully assessed within the evaluation procedure. Finally, according to the eligibility criteria, 55 articles resulted, which were adequate for the present work and were included in the final review (*Fig. 1*). F1

ANALYSIS METHODS

The selected articles for this review were divided into three categories based on their level of development. The first category included works that implemented technological solutions for the automatic assessment of one or more specific symptoms of PD. The designed protocol for these studies demanded that experimental sessions be performed in the home environment. The automated evaluation of PD impairments represents the first step toward a telemedicine system and allows the patients to automatically monitor their health status; this application is particularly valuable for the most disabling symptoms. The second category of articles encompassed studies in which a mobile application was developed for PD management. This category is a further step toward the fully automated assessment of the pathology at home, allowing the patients to use a highly common technological device (i.e., the smartphone) that could acquire data directly, process the data, and eventually provide timely feedback to the users. Finally, the third category featured researches in which telehealth services were designed and/or implemented. This class can include works from other categories, such as wearable solutions tested

in the home environment or mobile apps for PD. In addition, the class can provide the complete system architecture, which integrates wearable sensors, mobile/web-based applications, servers for the storage and elaboration of acquired data, and smart interfaces for communication between patients, caregivers, and medical staff (*Fig. 2*). F2

REPORTED RESULTS

More than half (52.7%) of the 55 fully evaluated articles were published during the past 3 years and 74.5% over the past 5-year period (*Fig. 3a*). This result confirmed the increasing interest for wearable systems in PD remote applications, as well as the need to improve telecare services for chronic patients. Thirty-one articles (56.4%) were published in journals, while the others were presented in international conferences. Regarding the application, 30 studies (54.4%) were tested in the home environment, 21 works (38.2%) implemented mobile applications, and 24 articles (43.6%) presented telehealth systems for PD. Nevertheless, only 4 articles (7.2%) concerned all three topics (*Fig. 3b*). F3

AUTOMATED SYSTEMS TESTED AT HOME

The possibility to have an automated evaluation of specific symptoms or disturbances can represent the first step toward a remote management of the disease. In particular, some impairments such as FOG,^{21–23} risk of falls,²⁴ motor fluctuations, and dyskinesias^{25–31} can mainly occur during specific times over the day. For this reason, it is not easy for the neurologist to evaluate the symptoms during a clinical examination at the hospital. The opportunity to measure and analyze motor performances at home can allow the patients to record their impairments precisely when they first appear, allowing the clinician to keep track of them over time. Accelerometers (ACC) and gyroscopes (GYR) are the most used sensors for these measurements (*Table 1*) because they represent a valid trade-off between unobtrusiveness and accuracy for motion measures.^{30,32–34} Furthermore, they can eventually be included in a smartphone,^{22,35} a wristband,²⁹ or a smartwatch,^{36,37} which are common technological tools, to increase the acceptability and usability of these systems.³⁵ These works aimed to address one or more symptoms, and their feasibility was typically measured by evaluating the ability of the system to discriminate PD patients from healthy subjects of controls (HC)^{26,38–45} or to correlate well with UPDRS clinical scores.^{26,30,40,41,46} Machine learning approaches (e.g., Support Vector Machine, Decision Tree, Random Forest, and Neural Networks) were generally implemented to evaluate the accuracy of the system in assessing the investigated symptoms.^{21–23,25,27,28,30,36,38,47} However, sometimes long-term studies involved a limited number of

Table 1. Studies Implementing Automated Systems for PD Assessment, Tested in Home Environment

| REFERENCE | TECHNOLOGY | SENSOR PLACE | RECORD.FREQ | DESIGNED PROTOCOL | SUBJECTS | EXTRACTED FEATURES | CLASSIFIER/CLASSIFIERS | ANALYSIS/CLASSIFIERS | CLASSIFIER PERFORMANCE OR FINDINGS |
|-----------|------------------------------|-----------------------------|--------------|--|---|---|---|---|------------------------------------|
| 21 | ACC, GYR | Waist | 200 Hz | Scripted activities and free ADL, including: (1) showing the researchers around their home; (2) Stand Up and Go test crossing through a doorway and then, turning back (up to 10 times); (3) going outdoors and taking a short walk; (4) dual task activity (20 min, both OFF/ON states) | 21 PD | A set of features, including: skewness, kurtosis, higher harmonics, autoregression coefficients, mean, SD | SVM (generic model vs. personalized model), sensitivity (sens.), specificity (spec.), geometric mean (GM) | Enhancement in GM: 72% for the personalized model compared to the generic model; 11.2% for the novel generic method compared to the traditional MBFA generic model; 10% for the novel personalized model with respect to the MBFA personalized model. | |
| 22 | GaitAssist app, smartphone | Ankles | 32 Hz | Participants deployed and used the system on their own, without any clinical support, at their homes, during three protocol sessions in 1 week. Exercises: gait initiations, additional dual tasking, turning exercises. | 9 PD | Power on locomotion band, Power on freeze band, Total Power, Freeze Index | C4.5 model | Real time hit rate 97% for FOG detection; detection delay of ≤0.5 s | |
| 23 | ACC, GYR | Each limb, waist | 62.5 Hz | Short-term recordings (15 min) in hospital: (1) lying on the bed; (2) rising from the bed and sitting on a chair located by the bed; (3) standing up from the chair and performing a series of tasks (walking, opening and closing a door, drinking, and random movements). Long-term recordings (8 h/day for 5 days) at home | Short term: 24 PD. Long term: 12 PD | Tremor: time and frequency domain features, LID: mean value, SD, entropy, energy in specific frequency sub-bands, and entropy of the frequency spectrum. Bradykinesia: approximate entropy, sample entropy, RMS value, cross correlation value, and range value. FOG: entropy | Hidden Markov Models (HMM), DT, SVM, RF | Classification accuracy: 87% for tremor, 85.4% for LID, 74.5% for bradykinesia, 79% for FOG. Mean absolute error: 0.088 for tremor, 0.31 for LID, 0.25 for bradykinesia, 0.79 for FOG | |
| 24 | ACC, GYRO, Kinect | Wrist | Not reported | Daily activities at home: (1) walking between rooms (e.g., to collect something); (2) preparing drinks or cooking; (3) sorting, washing, and hanging out clothes; (4) ascending and descending stairs; (5) negotiating steps between rooms; (6) crossing open spaces in large rooms | 5 PD at high risk of falling | Qualitative observations | Qualitative assessment | High risk of falling when people transferred between sitting and standing, walked, turned, negotiated steps, and tackled tasks while standing | |
| 25 | ACC, GYR | Each limb and waist | 62.5 Hz | 1st: laboratory, to test technical performance; 2nd: hospital, to test clinical compliance; 3rd: home, to evaluate system prototype; 4th: to test system wearability | 1st: 20 HC; 2nd: 36 PD 3rd: 44 PD and 12 Parkinsonism; 4th: 24 users | Features to measure dyskinesia (dysk), bradykinesia and tremor (e.g., step frequency, velocity, arm swing frequency, and entropy of gait signal) | DT, SVM | 93.73% accuracy (acc) for the classification of levodopa induced dysk (LD) severity: 86% acc. for bradykinesia severity and 87% acc. for tremor. Touch-screen PC was well accepted. | |
| 26 | ACC, GYRO | Ankles | Not reported | Everyday activities: making coffee, lying, sitting quietly, sitting and standing, dressing, 1st study: 6 h, laboratory-environment; 2nd study: 12 weeks in home-environment | 1 st : 23 PD (7 leg dysk), 13 HC; 2 nd : 10 PD (7 dysk) | Ratio of the angular rate around the z-axis over the angular rates lying within the xy-plane | Ad hoc algorithm for dysk detection; correlation coefficient | 85% sens., 98% spec., 0.96 acc. for dysk detection in laboratory environment; perfect discrimination in home environment; 0.61 ($p < 0.001$) correlation with UPDRS | |
| 27 | ACC | Waist | 200 Hz | 1 st : activities guided but execution free (e.g., indoor/outdoor walking, FOG provocation, dysk, false positive tests), before/after medical intake, at home; 2 nd : Laboratory activities (walking in a straight line, over an inclined plane, carrying a heavy object, setting a table, going upstairs and downstairs) and outside protocol (walking for >15 min) | 1 st : 92 PD, 2 nd : 10 PD (mild to moderate with motor fluctuations) | Power spectrum in dyskinetic band (0.68–4 Hz), nondyskinetic band (8–20 Hz) and posture transitions (0–0.68 Hz) | SVM (leave-one-out-subject) | 100% sens., 98% spec. for strong trunk dysk; 38% sens., 93% spec. for weak dysk on limbs; 93% sens., 98% spec. for all strong dysk or weak dysk on trunk | |
| 28 | Trigno™ (Dsys Inc): ACC, EMG | Distal portion of each limb | Not reported | 4 h continuously recorded during unscripted and unconstrained activities in a 100 m ² laboratory that simulated a studio apartment | Training set: 11 PD. Test set: 4 HC, 8 PD | Low pass energy, High pass energy, Lag and height of first peak in autocorrelation of ACC corrected signal | Dynamic NN (DNN) | >90% sensitivity (sens.), >90% specificity (spec) for moderate and severe levels of tremor and dysk | |

continued →

Table 1. Studies Implementing Automated Systems for PD Assessment, Tested in Home Environment *continued*

| REFERENCE | TECHNOLOGY | SENSOR PLACE | RECORD.FREQ | DESIGNED PROTOCOL | SUBJECTS | EXTRACTED FEATURES | ANALYSIS/CLASSIFIERS | CLASSIFIER PERFORMANCE OR FINDINGS |
|-----------|-------------------------------|-----------------------|--------------|--|------------------------|--|---|--|
| 29 | Kinesia™ (ACC, GYRO) | Wrists and ankles | Not reported | 6 ADL (2 h): (1) hygiene: brushing hair and teeth, (2) dressing: putting on/taking off a jacket and shoes, (3) eating: setting a table, eating a snack, and/or drinking a beverage, (4) desk work: writing on paper and using a computer, (5) entertainment: reading and/or watching television, and (6) laundry: folding towels and clothes from a basket | 13 PD with LID history | Tremor, dyskinesia, and bradykinesia before and after medical intake | ROC, AUC, radar charts, True Positive Rate, False Positive Rate, Correlation coefficient, Wilcoxon signed rank test | Algorithm scores for tremor, bradykinesia and dyskinesia agreed with clinician ratings of video recordings (ROC >0.8). Significant differences ($p < 0.01$, $p < 0.001$) in performances after and before medical intake. |
| 30 | ACC | Wrists | 100Hz | 1st study: 4 h in laboratory performing MDS-UPDRS III items (4, 6, 10, 11, 15 e 17) for upper limb bradykinesia, tremor, and gait. 2nd study: 7 days at home performing ADL | 34 patients | 91 features, including: Fourier coefficients, empirical cumulative distribution function features, and statistical features | Artificial NN (ANN) leave-one-out. Correlation coefficients | Dysk assessment: 0.38 sens, 0.99 spec, in laboratory, 0.49 sens, 0.93 spec at home; ON-OFF detection: 0.65 sens, 0.83 spec, in laboratory, 0.51 sens, 0.87 spec at home; Correlations: UPDRS IV dysk ($r = 0.52$, $p = 0.008$ (excellent diaries), $r = 0.52$, $p = 0.004$ (good diaries), UPDRS IV ON-OFF not significant; diaries/dysk ($r = 0.69$, $p = 0.001$ (excellent diaries), $r = 0.65$, $p = 0.002$ (good diaries), diaries/ON-OFF: $r = 0.63$, $p < 0.004$ (excellent diaries), $r = 0.56$, $p < 0.01$ (good diaries)) |
| 31 | ACC | Wrists, ankles, waist | 40 Hz | 4 days at home | 2 PD | Mean, energy, high frequency energy content, correlation and frequency domain entropy, a 5 bin histogram representation of the spectral contents over all 3 axes | Algorithm based on axis parallel rectangle (APR) fitting in the Feature Space | The APR based multiple instance learning algorithm had the best accuracy compared to other classification algorithm |
| 32 | ACC | Wrists | 100Hz | 1st study: 4 h in laboratory performing MDS-UPDRS III items (4, 6, 10, 11, 15 e 17) for upper limb bradykinesia, tremor, and gait. 2nd study: 7 days at home performing ADL | 34 patients | Questionnaire responses, wearing time of sensors | Likert-style questionnaire, Wilcoxon rank-sum test | Long-term monitoring with wrist-worn sensors is acceptable to this cohort of PD patients |
| 33 | ACC, GYR | Each limb and waist | 62.5 Hz | To wear the system at home and to move freely carrying out daily activities (5–7 days, running 2 sessions of 4 h/day) | 11 PD | Entropy and classic gait parameters (e.g., step frequency, velocity, stride length) | Wearability assessment | All participants agreed that the provided solution did not obstruct them in everyday activities nor did it effectively limit their activities |
| 34 | ACC, GYR | Each limb and waist | 62.5 Hz | Not specified (subjects tested the wearability of the system at home over time) | 32 PD | Wearability in terms of: energy cost, comfort, and biomechanical (pain, discomfort) | Rapid Entire Body Assessment (REBA), Borg and CRBS scales in combination with a body map | The acceptance of this system is satisfactory with all the levels of effect on each component scoring in the lowest ranges |
| 35 | IMU + smartphone + mobile app | Feet | Not reported | Gait training for 30 min, thrice per week for 6 weeks | 11 PD | Average time and distance walked, steps taken, cadence, gait speed, and both praising and corrective messages delivered per session by the app | Likert scale for usability | System usability was satisfactory |
| 36 | Smartwatch (GENEActiv) | Wrist | 50 Hz | 20 motor tasks divided into 5 groups (resting, gross upper limb movement, fine upper limb, periodic hand movement, and walking) repeated 6 times during 2 days of hospital visits, and 2 additional days of home monitoring. | 19 PD | Relative energy features and mean relative energy for each of the wavelet scales | Wavelet, SVM (19-fold cross validation), ROC, AUC | AUC=0.75 for rest dyskinesia; AUC=0.92 for walking dyskinesia; AUC=0.70 for bradykinesia |
| 37 | Smartwatch + EchoWear app | Wrist | Not reported | Month-long in-home trial involving commonly used speech tasks; sustained vowel phonation, low and high pitch range | 6 PD | Perceptual Loudness, zero-crossing rate, spectral centroid, short-time energy | Qualitative assessment | Configurability, computational intelligence, and interoperability of the interface for remote monitoring of speech treatments |

continued →

Table 1. Studies Implementing Automated Systems for PD Assessment, Tested in Home Environment continued

| REFERENCE | TECHNOLOGY | SENSOR PLACE | RECORD/FREQ | DESIGNED PROTOCOL | SUBJECTS | EXTRACTED FEATURES | ANALYSIS/CLASSIFIERS | CLASSIFIER PERFORMANCE OR FINDINGS |
|-----------|--|--|--------------|--|---|--|--|---|
| 38 | ACC, GYRO, CSAS Smart home, smartphone | Upper dominant arm, ankle of dominant side | 30Hz | 1ADL: water plants, medication management, wash countertop, sweep and dust, cook, wash hands, TUG test, TUG test with name generation, Day Out Task | 1 st , 2 nd PD, 50 HC, 2 nd : 9 Mild Cognitive Impairment (MCI), 16 PD/MCI, 9 PDMCI, 18 HC | Ambient sensor features, wearable sensor features, day out task features, participant features, activity features | DT, Naive Bayes, RF, SVM, AdaDT, AdaRF, ANOVA, ROC | 0.74 AUC, 0.75 acc. (individual tasks), 0.70 AUC, 0.70 acc. (combined tasks) for PD/HC recognition with AdaRF, 0.96 AUC, 0.85 acc. (individual tasks), 0.64 AUC, 0.32 acc. (combined tasks) for PD/MCI/PDMCI/MCI/HC recognition with AdaDT. Best performance using all sensors and all activities |
| 39 | Body worn monitor (BWM) with ACC | Waist | 100Hz | (1) Laboratory data; 4 intermittent straight line walking trials over a 10-m walkway at preferred speed. (2) Free-living gait data collected over 7 days | 47 PD, 50 HC | 14 gait characteristics (e.g., step velocity, step length, and swing time) representative of five domains (pace, variability, rhythm, asymmetry, and postural control) | Shapiro-Wilk test, t-tests or Mann-Whitney U, Wilcoxon signed-rank tests, Spearman rank-order correlations | The impact of environment was significant for all gait characteristics ($p < 0.001$). Between-group differences in gait characteristics were exaggerated in free-living conditions. Free-living data showed low to moderate correlations ($r \leq 0.453$) with laboratory results for both groups. ABS $\leq 10^{\circ}$ s did not discriminate between groups. Medium to long ABS highlighted between-group significant differences for pace, rhythm, and asymmetry |
| 40 | Opal inertial sensors (APDM, Inc., Portland, OR, USA) | Belt and feet | Not reported | 10h per day, 7 consecutive days during normal daily activities | 13 PD, 8 HC | Mean and CV of: (1) number of turns per hour, (2) turn angle amplitude, (3) turn duration, (4) turn mean velocity, and (5) number of steps per turn | Shapiro-Wilk test, One-way Analysis of Variance, Pearson's correlation coefficients | PD showed impaired quality of turning compared to HC in turn mean velocity and mean number of steps. PD showed higher variability within the day and across days compared to HC. No differences between PD and HC in number of steps per day or of the day walking during the 7 days. Statistically significant correlation between CV of turn velocity ($r = -0.79$, $p = 0.01$), the number of steps per turn ($r = 0.61$ and $p = 0.03$), and turn velocity ($r = 0.61$, $p = 0.03$) with the UPDRS motor score. |
| 41 | Mobi8 TMSI (ACC), DynaPort Hybrid Monitor (ACC, GYR) | Lower back | 256Hz | Validation study: 1 min, straight-line walk at a self-selected comfortable pace inside a long hallway. Gait test: straight-line walk (~25 m \times 2). ADL simulation: 500 m walk at comfortable self-selected speed. Monitoring at home: 3 consecutive days | Validation: 22 PD, 17 HC. Monitoring: 1 PD, 1 HC | Stride time and stride time variability (validation study only). Dominant freq, amplitude, width (FD), and slope of the main freq of the PSD in the 0.5- to 3.0-Hz band | t tests 2-tailed; paired t tests; Pearson coefficients | Width larger and amplitude and slope smaller in PD compared to HC validation study and ADL simulation ($p < 0.02$). Width decreased and amplitude and slope increased with anti-Parkinsonian medications ($p < 0.007$). Significant correlations ACC-derived measures/UPDRS-Gait5. Home data were similar to the clinic data. |
| 42 | Physilog® (ACC, GYR) | Shanks, wrists, sternum | 200Hz | iTUG test at home within 24 h before or after laboratory testing | 6 PD, 8 HC | Stride length, stride velocity, cadence, peak arm swing velocity on the more affected side (MAS), and turning velocity | Repeated Measures ANOVA; post-hoc comparison Tukey-Kramer tests | Significant group effect for stride velocity ($p = 0.03$), cadence ($p = 0.001$), peak arm swing velocity MAS ($p = 0.002$), and turning velocity ($p = 0.003$). Significant interaction effect for stride velocity ($p = 0.02$) and stride length ($p = 0.002$). Significant location effect for turning velocity ($p = 0.002$) |
| 43 | ACC, GYR | Wrists, ankles, trunk | Not reported | Subjects were continuously monitored at home over a 9-h period while performing their normal daily activities | 10 HC, 6 PD | Tremor index: ratio of the power within frequency range of 4–8 Hz to the power of total rotation within frequency range of 0.1–8 Hz | Spectrogram | Significant differences were detected between PD/HC before and after medical intake |
| 44 | Opal inertial sensor (APDM, Inc., Portland, OR, USA) (ACC, GYR, MAG) | Pelvis | 128Hz | Laboratory: to walk on a path of a mixed route with short straight paths interspersed with 10 turns of 45°, 90°, 135°, and 180° in both directions, at different speeds (12 times). Home: monitoring about 10 h/day for 7 days | Laboratory: 21 PD, 19 HC, Home: 12 PD, 18 HC | Bouts, hourly frequency of turning, duration of each turn, number of steps per turn, peak and average rotational turning rate, jerk, variability of these measures throughout the day and week | Sens. Spec. | Laboratory: 0.90 sens., 0.75 spec. compared to motion analysis; 0.70 sens., 0.65 spec. compared to video analysis. PD had a slower velocity and higher impairements compared to HC while turning. Home: significant differences between HC/CPD in bout duration, active rate, turning duration, angle of turning, peak velocity of turning, number of steps for turning. |

continued →

Table 1. Studies Implementing Automated Systems for PD Assessment, Tested in Home Environment: continued

| REFERENCE | TECHNOLOGY | SENSOR PLACE | RECORD.FREQ | DESIGNED PROTOCOL | SUBJECTS | EXTRACTED FEATURES | ANALYSIS/CLASSIFIERS | CLASSIFIER PERFORMANCE OR FINDINGS |
|-----------|---|---|--------------|--|--------------|--|--|--|
| 45 | ACC, GYRO, smartphone + audiofeedback (ABF-gaitapp) and the instrumented cueing for FOG-training (FOG-cueapp) | 100 Hz | Gait, FOG | Gait training for 30min, 3 times per week for 6 weeks | 20 PD, 18 HC | Gait speed, stride length, double support time | Kolmogorov Smirnov analysis and Levene's test, t-test, Fisher's LSD post-hoc analysis for effect size. | $p<0.001$ for gait speed and stride length, $p<0.01$ for double support time both for PD and HC. PD improved more than HC both in comfort and dual task condition. Effect size: small for HC, moderate for PD. |
| 46 | ACC | Waist | Not reported | Walking free to show the home (>2 min); walk without assistance (10 m) (both in OFF/ON states) | 75 PD | A single frequency feature consisting of the power spectra between 0 and 10 Hz | Spearman's correlation coefficient | Moderate correlation with UPDRS-III ($r=-0.56$; $p<0.001$). Good correlation with gait item ($r=-0.73$; $p<0.001$). Good correlation with Factor 1 (axial function, balance, and gait) ($r=-0.67$; $p<0.001$) |
| 47 | FAB System BioSyn® (ACC, GYRO) | head, arm, forearm, trunk, pelvis, thigh, shank | 100 Hz | Walking, walking turns of 180°, and fast walking (3 trials) at home | 11 PD | Mean and peak amplitude values of each of 59 joint variables | Change space: Least Absolute Shrinkage Selection Operator (LASSO) | Correctly predicted 5 cases of improvement and 2 cases of worsening after medication |
| 48 | ACC, EMG sensors | Forearms, arms, thighs, shanks | Not reported | 3 days, (2 days in clinical setting, 1 day in home setting). Longitudinal study. Heel tapping (30 s), forearm pronosupination (30 s) | 5 PD | Intensity, modulation, frequency, periodicity, smoothness of movement, signal entropy | Relief and Davies-Bouldin (DB) cluster validity index; RF with 20 trees; Scatter Plot | Scatter plot visually showed a trend from a score of 1 to a score of 4. RMS ≈ 0.4 error in the estimation of the UPDRS score |
| 49 | ACC, GYR | Each limb, trunk, pelvis, head | 100 Hz | 1st: walking and turning, sitting and rising from a chair, figure 8 turns, reaching tasks. 2nd: free daily activity (1 h) | 11 PD | Inter-trial variability, inter-task variability | Principal Component Analysis (PCA) | Very large variability among PD patients |
| 50 | 3 IMU (ACC, GYR) + Wii Balance Board + smartphone + mobile app | Not reported | | Gait, hypokinesia, dysk, tremor and sleep | 22 PD | ADL and sleep monitoring, balance, and cognitive tests 24/7 over 12 weeks (4 weeks without feedback and 8 weeks with feedback) | MDS-UPDRS, H&Y, Montreal Cognitive Assessment (MoCA), MMSE, PDD-38, EQ-5D, Epworth Sleepiness Scale (ESS), Pain/Disorder Severity Scale (PDSS), Nonmotor Symptom Scale (NMSS), Unified Dyskinesia Rating Scale (UDysRS), Clinical Global Impression - Severity Scale and Improvement Scale (CGI-S and CGI-I) | Acceptance level of PD patients using the SENSE-PARK System as a home-based 24/7 assessment is very good |

Table 2. Studies Implementing Mobile Applications for PD

| REFERENCE | TECHNOLOGY | RECORD. FREQ. | SYMPOTM/ IMPAIRMENT | DESIGNED PROTOCOL | SUBJECTS | EXTRACTED FEATURES | ANALYSIS/ CLASSIFIERS | CLASSIFIER PERFORMANCE OR FINDINGS |
|-----------|--|---------------|---------------------|---|---|---|---|--|
| 52 | Smartphone (ACC,GYR) + sTUG app | 100 Hz | Gait and posture | To perform the TUG test in the shortest amount of time (3 times) | 3 PD, 4 HC | Total duration of: TUG, sit-to-stand transition, stand-to-sit transition. Subphase duration, maximum angular velocities, and upper trunk angles | N/A (mean and SD) | PD patients needed more time to complete the total test, as well as the individual phases of the test. HC had notably higher maximum angular velocity during the lift up phase. The duration of the stand-to-sit phase for HC was notably shorter than PD. |
| 53 | Smartphone (ACC) + mobile app | Not reported | Tremor | Resting task (10s, 10 trials) | 1 PD, 1 HC | Frequency (PSD) and spatiotemporal (mean averaged acceleration, SD, CV) | T-test | Statistical difference between PD/HC ($p < 0.05$) |
| 54 | Smartphone (ACC) + mobile app | 60 Hz | Tremor | Resting task, Postural task, Intention task, Kinetic task (bringing the phone to one's ear and back at a relatively slow velocity). | 12 PD, 3 ET, 1 multiple sclerosis | Tremor amplitude, regularity, power distribution (3–7 Hz), median, peak of power freq, power dispersion, harmonic index. | Pearson coefficients | Tremor amplitude correlation to clinical scale: $r = 0.76$ for RT; $r = 0.85$ for PI; $r = 0.88$ for tremor amplitude for intention tremor; $r = 0.09$ for KT, $r = 0.7$ for power distribution in KT. |
| 55 | Microsoft Band (ACC, GYR) + Android app for smartphone | 62.5 Hz | Tremor | 1st: simulated tremor and hand posture; 2nd: Resting task, Postural task, ADL; 3rd: several hours recording | 1st: HC; 2nd: 11 PD; 3rd: 1 HC, 2 PD | Energy, energy ratios, principal components, tremor amplitude, tremor frequency | C4.5 DT 10-fold cross-validation; Pearson's coefficient | 94% acc. for tremor detection; 85% acc. for RT/PI discrimination; $r = 0.95$ for UPDRS correlation of tremor amplitude, $r = 0.97$ for UPDRS correlation of tremor constancy |
| 56 | 1-channel ECG wearable sensor + smartphone running on Android 6.0 "Marshmallow" equipped with a gravity sensor, a magnetic sensor, and a step detector sensor + DailyHeart app | 256 Hz | Cardiac activity | 1st: to sit on a chair, stand up on command and walk forward for 5m (5 times). 2nd: to sit on a chair for 3 min (adaptation to current posture). ECG measurement started, the subjects had to remain seated for 1 min, stand up on command, and stand still for 1 min (3 times) | 1st: 10 young HC. 2nd: 3 HC, 5 PD (not age matched) | 1st: recognition rate of the algorithm, time difference between automated and manually labeled stand-up event. 2nd: Average and SD of RR intervals, average and SD of successive differences, root mean square of successive differences, number of successive differences ≥ 20 ms divided by all RR intervals | DT based on a leave-one-subject-out cross-validation | Recognition rate of 90.0% for the stand-up detection algorithm. 96.0% acc., 93.3% sens. 100% spec. for HC/PD classification. PD patients showed a considerably lower orthostatic reaction than HC |
| 57 | WiFit, sensorized cane (ACC), infrared temperature sensor, smartphone + mobile app | Not reported | Falls | Fingertip temperature | 10 subjects | Signal vector magnitude and tilt angle | Fuzzy rules | 81.67% acc. for fall detection. 2.88% average error in predicting fingertip temperature |

Table 3. Studies Designed/Implementing Telehealth Services for PD

| REFERENCE | PORTABLE TECHNOLOGY | SYMPTOM/IMPAIRMENT/TASKS | SYSTEM ARCHITECTURE | PRIVACY/DATA TRANSFER ISSUES | PILOT TESTS ON PD | FUNDING |
|-----------|--|--|---|---|--|--|
| 22 | GaitAssist with IMU on ankles, smartphone | FOG | IMU sensors, FOG-detection module, Motor-training exercise module, Preference module, Auditory feedback module, Telemedicine and logging module, patient UI, clinician UI | Logging module | Dataset: 9 PD. Results: see Table 1 | EC under the FP7 project CupID (288516) |
| 23 | ACC, Gyr on each limb and waist | Tremor, LID, bradykinesia, FOG | Wearable Multi-Sensor Monitor Unit + Local Base Unit (Daily Monitoring Processor (composed of: Tremor Posture and Resting Recognizer, and Activity Recognizer) + Test Processor + Scheduler + Information Handler) + Centralized Hospital Unit (Alert Manager + Information Manager + Interoperability Manager) | Encrypted messages for transmission | Dataset: 24 PD in hospital, 12 PD at home. Results: see Table 1 | EC under the FP7 project PERFORM (215952) |
| 35 | ACC, Gyro, smartphone on the feet | Real-time gait analysis | IMU + smartphone + telemedicine service for remote data upload | Encrypted transmissions using the SSL protocol (https://); authentication page for the login | Dataset: 11 PD. Results: System acceptability evaluation | EC under the FP7 project CupID (288516) |
| 37 | Smartwatch | Speech analysis | Smartwatch (EcoWear app), Fog Computing Platform (Intel Edison), Cloud | The Secure Copy Protocol (SCP) was used for transfer of files and directories between two hosts (local or remote). | Dataset: 6 PD. Results: qualitative (see Table 7) | Rhode Island Foundation Medical Research (20144261) |
| 48 | ACC, EMG sensors on forearms, arms, thighs, shanks | Heel tapping and forearm pronosupination | MercuryLive System, 3 tiers: (1) patient's host with wearable sensors and laptop, (2) clinician's host for patients' supervision and annotation tools, (3) central server coordinating data collection and videoconferencing services | Not reported | Dataset: 5 PD. Results: see Table 1. | Michael J. Fox Foundation |
| 58 | 2 insides (Moticon), smartphone in the pocket, wristband (Microsoft band) | Motor and nonmotor symptoms, including ON/OFF fluctuations | PD_manager platform: (1) clinicians' app (events for patients, therapy, communication with other health professional), (2) patients' app (recommendations for modifications in therapy and treatment), (3) caregiver's app (feedback symptoms and medical adherence) | Not reported | Dataset: 20 PD. Results: N/A | EC under the Horizon 2020 project PD_manager (643706) |
| 59 | Smartwatch, smartphone, fall detector, Philips Mobility Monitor (ACC, barometer) | ADL | Smartwatch + smartphone (with Fox /Insight app) + Cloud platform (Radbourne data server, Amazon Web Services, ZenDesk software and servers) | Plan for: coding the data storing the data on secure servers, separately from personal data, and restricting data use by only allowing access to authorized researchers. When making information available to the wider research community, data will be anonymized and access will be granted only through a secure research database. | Dataset: 20 PD. Results: 88% streaming compliance for the sensor data | Michael J. Fox Foundation, the Intel Corporation [Tel Aviv, Israel], Philips Research, Stichting Parkinson Fonds, and the Movement Disorders Society |
| 60 | SmartButton (ACC, GFR, MAGN) on the chest | Mobility: 10s and 30-s Chair Stand tests | Smartwatch (with Radbourne data server, Amazon Web Services, ZenDesk software and servers) | Authentication and secure communication | N/A | U.S. National Science Foundation under grants CNS-1205439 and CNS-1217470. |
| 61 | Smartphone (ACC) on hand or ankle | Hand resting tremor and gait | Mobile app (PD Di) on smartphone with (1) user log-in and account verification, (2) motor performance test module, (3) communication module with SMS and email, (4) test history management module + cloud service: data processing and decision-making | Privacy and data security are assured; in the mobile app, user log-in is required. All data stored are encrypted (Advanced Encryption Standard [AES]), any patient identity information are stored or displayed (according to Health Insurance Portability and Accountability Act (HIPAA) regulations). The data are deleted from the device after sending to the cloud service. At the transmission level, data are encrypted and transmitted through secure https. At the server level, data are stored in the database in encrypted format and only an authorized database administrator has access. | Dataset: 40 PD. Results: 0.77 secs., 0.82 acc for hand resting tremor, 0.89 secs., 0.87 acc for gait difficulty detection. The system is simple to use, user friendly, and economically affordable | Not reported |

continued →

Table 3. Studies Designed/Implementing Telehealth Services for PD *continued*


| REFERENCE | PORTABLE TECHNOLOGY | SYMPTOM/IMPAIRMENT/TASKS | SYSTEM ARCHITECTURE | PRIVACY/DATA TRANSFER ISSUES | PILOT TESTS ON PD | FUNDING |
|-----------|---|--|--|--|---|--|
| 62 | ACC, GYR, compass on each limb and waist | Exercises from UPDRS | Sensor units, smartphone, application server, database server, and browser application | Specified communication systems (e.g., IEEE 11073 messages, HL7 Version 2 data exchange format) | N/A | Ministry of Science, Research and the Arts of Baden - Wuerttemberg |
| 63 | Smartphone and smartwatch (ACC) | Standard hand tremor tests, finger tapping tests, involuntary tapping and spiral-drawing tests | Android mobile phone, an external ACCSmartwatch, and a web server (Parse) that maintains mongo databases and uses a BSON Handler to communicate with the phone. Software architecture of the system consists of a data centered architecture built around the database and an object-oriented architecture (Java) for developing Android code, which by default uses call and return architecture. | Each user entity is also linked to an authorized session; sessions may expire when the user is idle or logs out. | Dataset: 11 subjects. Results: 95% acc. in PD identification | Not reported |
| 64 | Smartwatch (ACC), smartphone | Facial recording; Speech recording; Typical MDS-UPDRS III tasks | Three layers: Body sensor network + Multidimensional diagnostic monitoring + personalized tele-interventions | Not reported | Dataset: 5 HC. Results: qualitative evaluation of the usefulness | Not reported |
| 65 | Microsoft Band (ACC, GYR), Sensor insoles, SimpleMed+ pillbox, smartphone | Gait, FOG, bradykinesia, dystonia, ON/OFF fluctuations | Mobile app for patients (modules: sensor monitoring, finger tapping, cognition battery, speech analysis, nutrition); mobile app for healthcare providers (modules: clinical record, patient assessment, calendar, nutrition, digital evaluation test, medication); notifications and alert systems (including DSS); educational gallery | All data are transferred using HTTP within a connection encrypted by transport layer security (TLS) or SSL. The TLS/SSL encryption is performed before any HTTP communication. So the whole interaction is protected. The client/users authentication interfaces are implemented following the OAuth 2.0 authorization framework specifications. | Dataset: 17 PD for gait, 11 PD for tremor, 13 PD for bradykinesia. Results: correct estimations: 69% for gait score, 9.1% for gait disturbance, 91% for FOG events, 94% acc. for tremor, 92% acc. for dysk, 92% acc. for bradykinesia | EC under the Horizon 2020 project PD_manager (643706) |
| 66 | ACC, GYRO, smartphone on the feet | Real-time gait analysis | IMU + smartphone + telemedicine service for remote data upload | Data logging thread | Dataset: 12 HC, 16 PD. Results: 29% total RMS difference on step length estimation between this system and gold standard | EC under the FP7/project CupID (288516) |
| 67 | Mercury Live with 9 ACC on forearms, arms, thighs, shanks, and waist | Monitoring | MercuryLive, System 3 tiers: (1) patient's host with wearable sensors and laptop, (2) clinician's host for patients' supervision and annotation tools, (3) central server coordinating data collection and videoconferencing services. | Securely encrypted services, including Secure Socket Layer (SSL), Secure Shell (SSH), and virtual private network (VPN). Using secure channels, both patients and clinicians' software clients can access the database, web server, videoconferencing services, and a live data forwarding service to perform background data logging and live interactive sessions. | Dataset: Not specified PD @home. Results: N/A | Michael J Fox Foundation |
| 68 | Gastromeniuss Expansion Measurement Unit (GEMU) based on a force-sensing resistor (FSR) (CP0152 (Interlink, USA)) | Step counting and dopaminergic therapy monitoring | FTP server Web-based distributed authoring and versioning software | Data transmission test resulted in: 80Kb/s of bandwidth available; 400 ms data latency, 200 ms video latency | Dataset: Not specified PD @home. Results: N/A | Italian Ministry of Health under the project CASE |
| 69 | Smartphone (ACC, GYR) in custom-made glove case | Resting tremor, postural tremor | Plan for applying cryptography to all communications from the smartphone to servers (e.g., SSL encryption) | Dataset: 25 PD, 20 HC. Results: 82% sens. 90% spec. for PD/HC classification with ensemble of DT | Not reported | Italian Ministry of Health under the project CASE |
| 70 | HELP system: intraoral device, subcutaneous pump, IMU on waist, blood pressure sensor on arm | Monitoring drug delivery | (1) A Body Sensor and Actuator Network (portable/wearable and home devices to monitor health parameters and body activity and to release controlled quantity of drugs in an automatic manner). (2) A remote Point-of-Care unit to supervise the patients under clinical specialist control | Not specified | N/A | EC through wearIT@work, CHRONIOUS, and Help-AAL |

continued →

Table 3. Studies Designed/Implementing TeleHealth Services for PD *continued*

| REFERENCE | PORTABLE TECHNOLOGY | SYMPTOM/IMPAIRMENT/TASKS | SYSTEM ARCHITECTURE | PRIVACY/DATA TRANSFER ISSUES | PILOT TESTS ON PD | FUNDING |
|-----------|---|---|--|---|--|--|
| 71 | Smartphone (ACC, GYR) to FOG Place on chest, waist, pocket, or ankle | | Server and client applications: the client application (remote sensing) was installed in a smartphone. Other smartphone fixed to the patient's body was running server application (receive messages to start and stop measurement from the client program). | Socket communication between devices | Dataset: 15 PD. Results: 86% sens. with sensors on the wrist using AdaBoostM1 classifier | SNUH Research Fund (342014050) |
| 72 | ACC on forearms, arms, thighs, shanks | MDS-UPDRS III tasks | MercuryLive. System 3 tiers: (1) patient's host with wearable sensors and laptop, (2) clinician's host for patients' supervision and annotation tools, and (3) central server coordinating data collection and videoconferencing services. | SSL and SSH for establishing secure channels for all data transfer | Dataset: late PD. Results: classification error 3.4% for tremor, 2.2% for bradykinesia, 3.2% for dyskinesia. | Michael J Fox Foundation |
| 73 | ACC on wrist + Personal Digital Assistant (PDA) | Tremor | Mobile unit with PDA (the server) + Hospital unit with central station PC (the client). TCP/IP communication and error handling protocols. The software contains three modules: (1) characteristics of the patient and results of the examination; (2) acquisition of signals during examinations; (3) receiving medical recommendations from the hospital unit. | Instrument access (username+password), data security, Bluetooth security procedures based on a L2CAP (Logical Link Control and Adaptation Protocol) implementing translation of data into secret code based on the SAFER (Secure And Fast Encryption Routine) and block cipher encryption algorithms. The identity of the device is cryptographically authenticated previously to start communicating. Data interchange in the internet performed using International Mobile Telecommunications-2000 (IMT-2000) standards (3G). | Dataset: 10 PD, 10 HC. Results: 100% sens. 100% spec. to detect adverse effects of disease with frequency features of tremor | Brazilian Council for Scientific and Technological Development and Rio de Janeiro State Research Supporting Foundation |
| 74 | Wristband (ACC, GSM/GPRS) | | | Internet transmission tests were conducted in laboratory and in three private homes, and the observed velocities may be considered adequate for the desired application | N/A | Not reported |
| 75 | Nintendo Wii Remote (NVR) with ACC in the hand and IR camera | Motor performances executing mini-games | Patient mobile unit (sensors) + Hospital Unit (presentation, diagnostic, and storage) | Socket method to establish communication connection between request (client) and service provider (server) | Dataset: 5 HC. Results: simulated symptom group is well recognized from the health group. | Department of Employment and Learning Higher Education Innovation Fund (Ulster University, North Ireland) |

ROVINI ET AL.


**Fig. 1.** Selection flowchart according to PRISMA statement.

of applications developed and downloaded.⁵¹ The idea to design mobile apps for monitoring and assessing one or more symptoms in PD reflects the patients' needs to have an objective support for health monitoring during their daily activities without impact on them, both physically and socially. In *Table 2* are reported only the works in which a mobile app was developed; m-apps tested at home are already reported in *Table 1*,^{22,23,35,37,45,50} and articles that included m-apps in a complete telemedicine system are reported in *Table 3*. The mobile apps can be used directly on the patient's own smartphone or smartwatch, without additional devices, minimizing their obtrusiveness,^{22,37,52–54} or they can be integrated with other sensors to improve the measurement


subjects, so classification approaches were unreliable, and the statistical analysis was limited to significance and correlation of the features,^{29,39–42,45,46} or it was conducted only visually^{43,48,49} or qualitatively.^{24,32–35,37,50} In *Table 1* are reported all the articles that performed tests at home (or simulated home^{28,29}), including systems implementing also mobile apps,^{45,50} a Web-based telemedicine system,⁴⁸ and the combination of all these topics.^{22,23,35,37}

MOBILE APPS FOR PD

In agreement with the large use of smartphones in the population, mobile applications (m-apps) are commonly used in many fields (e.g., gaming and fitness). Healthcare, in particular, is one of the most typical fields for number

**Fig. 2.** The architecture of a general telehealth system.

WEARABLE SENSORS FOR PARKINSON'S DISEASE AT HOME



AU7

Fig. 3. Publication trend per year (a); paper distribution per application (b).

capability.^{23,35,55–57} They can allow the recording of specific exercises (e.g., tremor analysis and TUG test),^{52–54} as well as monitoring and recording of patients over several hours.^{23,35,50,55} The apps can offer corrective feedback as well, encouraging the patients, for instance, to improve their physical activity or medical adherence.³⁵

TELEHEALTH SYSTEMS

The implementation of e-Health or IoT systems is currently the final goal to have a valid solution for PD remote management (*Table 3*). Such systems included automated systems for the assessment and/or monitoring of specific symptoms,^{22,23,35,37,48} and they developed also mobile^{58–66} or Web-based^{48,67–69} applications that allow both the patients and the clinicians to easily access the system through appropriate user interfaces. These systems would practically provide a modern telemedicine service using cloud platforms and server applications in which smart algorithms are implemented to analyze the acquired data (*Fig. 2*). Such systems allow a large amount of data to be transferred and managed, providing both the clinicians and the patients with useful information about disease progression and health conditions. Long-term monitoring at home,⁶⁷ eventually during activities of daily living (ADL),⁵⁹ can be useful for the management of both early-mild patients by permitting the evaluation of the response to drug delivery^{68,70} and for mid-advanced patients in which severe impairments such as ON-OFF motor fluctuation,^{58,65} levodopa induced dyskinesias,²³ and FOG^{22,71} often appear. The motor analysis of standardized MDS-UPDRS III tasks (e.g., forearm pronosupination, heel tapping, gait, and tremor)^{35,48,60–64,66,69,72–74} is another fundamental application that enables clinicians to have objective results about patients' motor performance over time, supporting remote differential diagnosis. Motor performance could also be assessed during ADL⁵⁹ or by executing virtual games.⁷⁵ Alternative systems involved speech analysis³⁷ and facial recognition⁶⁴ as well, which can add useful information about disease onset and progression, as described in MDS-UPDRS tasks 3.1, 3.2. Since sensitive data are acquired, processed, and stored in the cloud, secure data

transmission and privacy represent important issues to address by adopting preventative measures for data protection.^{23,35,37,60,61,63,65,67,68,71–74}

Discussion

The increasing rate in age-related pathologies such as Parkinson's disease is causing an increase of chronic pa-

tients, with worsening in their QoL. These people need long-term treatments, therapy adjustments, and monitoring, but often, clinical examinations in hospitals are not sufficient for optimal management of the pathology due to long waiting lists, high traveling distance, working hours lost, etc. The possibility to monitor the patients at home enables the evaluation of many aspects that are not always evident or are infeasible to assess during neurological examinations in clinic, including motor fluctuations and dyskinesias,^{25–31} freezing events,^{21,71} response to therapy adjustments before and after medical intakes,^{29,43,47} and eventually correlated pathologies (e.g., cardiac activities).⁵⁶ Furthermore, the use of a monitoring system in the home environment could eliminate the "white coat effect," which is responsible for better performance in the hospital rather than during daily living activities.^{44,56}

Acceptability,^{32,34,68} usability,^{35,50,62} and wearability³³ are all considerations that require particular attention to have an efficacious system that will actually be used by patients, without affecting their daily activities, both physically, avoiding impairments due to obtrusive heavy devices, and socially, avoiding devices that could be embarrassing and invasive for the users when they are in the community. For these reasons, the use of smartphones^{52,56} or jewelry-like wearable sensors,^{76,77} which are common technological tools, seems to be the best solution to have a portable inexpensive instrument, which is socially accepted and easy to use. Particularly, using internal sensors and algorithms of a smartphone prevents the need for additional hardware, almost for some kind of assessment.

Usability and acceptability from users' perspective are important issues for an operative and effective telemedicine system, as mentioned in several articles included in this review. Nevertheless, just few works reported quantitative results about them. In particular, Ferrari et al.³⁵ administered to the users a questionnaire based on a five-point Likert scale for the CUPID system usability and feasibility evaluation. They reported a satisfactory result, with a mean value of 4.5 out of

ROVINI ET AL.

5. Similarly, Ginis et al.⁴⁵ also investigated usability for the CUPID system, obtaining very positive responses, as scores on user-friendliness were on average above 4 on a 5-point scale. Ferreira et al.⁵⁰ also proposed to assess the usability of another system, the SENSE-PARK system, that achieved mean score of 2.67 out of 5 on the PSSUQ.

Another matter of debate is the optimal number of sensors to use, because preliminary results suggested that reducing them may lead to loss of potentially relevant information, especially for PD patients, who show a large variability in movements.⁴⁹ However, in accordance with literature, generally less than four sensor devices were used.⁵⁸ Anyway, energy harvesting approaches should be investigated because devices with long battery life are mandatory for long-term monitoring in unconstrained environments.^{72,73}

The use of a tele-system for automated assessment of PD symptoms could support the neurologist in remote differential diagnosis, as well as through decision-making support systems.^{58,65} While the test results are automatically uploaded into patient medical records, the system could provide instantaneous feedback to the users,^{35,52,66} allowing the patients to obtain immediate results about their current condition without the direct involvement of any clinics.⁶³

Since telehealth systems acquire and manage a wide amount of data, machine learning techniques are needed for their processing, analysis, and aggregation; thus, the results could be appropriately showed to patients and/or clinical staff, through smart user interfaces.^{22,23} Technically, the management of a large amount of data requires attention to data loss and correct transmission of data.^{25,67,73} Ethically, since sensitive data are acquired and processed, adequate measurements for data protection should be applied, including restricted and authenticated access to data,^{22,60,63} secure encrypted data transmission (e.g., SSL, SSH, VPN, and TLS protocols),^{65,67–69,72} and anonymized personal data.⁵⁹

As limitation, most of the articles included in this review involve a limited number of subjects in the experimental sessions and have a lack of randomization, potential recall bias, and likely selection bias. Thus, the clinical validation of the proposed systems cannot be addressed,⁷³ and further investigations are required. In addition, sociocultural factors are usually not investigated in these works; therefore, there is a lack of information concerning the influence of relatives on telemedicine services and how gender, education, and working condition could affect their design and provision.

Finally, the development of telehealth systems is a step beyond the simple use of wearable sensors at home, because it means actively including patients and caregivers in the

healthcare path,²⁵ promoting their empowerment in the management of their health status and disease progression through a conscious involvement.⁵⁸ The concept, indeed, is to transform the patients from end users to the main actors of the healthcare process, favoring the participation and cooperation of patients, caregivers, and clinical staff²⁵ to provide the best care available for each patient according to the precision medicine approach. Appropriate training sessions would be organized to enable people to correctly use the system. The possibility to have a more personalized therapy³¹ seems also to increase the feeling of assurance of the patients regarding the appropriate healthcare path to follow.⁶⁵

Generally, the adoption of telemedicine should be accompanied with the transformation of healthcare sector and overcome specific barriers. In terms of organization of the healthcare sector, reimbursement profiles should be defined considering which patients may benefit most and understanding the optimal frequency of telemedicine visits as replacement for in-person encounters.⁷⁸ Furthermore, a uniform regulation is missing in the domain of medical liability, at national and international level, thus hampering the development of telemedicine market in health services.⁷⁹ Telemedicine requires ubiquitous, adequate affordable broadband to support health information exchange to increase access to quality care for all individuals at the right place and the right time when it is needed.⁷⁸

Conclusions

This review article provides an exhaustive overview of automated systems based on wearable and portable technologies for remote assessment and management of Parkinson's disease. The articles were divided into three categories according to the level of development of the implemented system, considering the automatic evaluation at home of PD symptoms and impairments, the development of mobile applications for PD assessment, and the design of e-Health systems for a complete remote healthcare service. Although they raised limitations, the use of such systems has the potentiality to enhance the PD management and treatment, supporting clinicians in remote monitoring and promoting the active engagement of the patients and their caregivers in the healthcare path. This aims to improve both patients' QoL and clinicians' quality of care toward an optimal personalized therapy.

Acknowledgment

This work was financially supported by the DAPHNE project (Regione Toscana PAR FAS 2007–2013, Bando FAS Salute 2014, CUP J52I16000170002).

WEARABLE SENSORS FOR PARKINSON'S DISEASE AT HOME

Authors' Contributions

ER was responsible for article structure and writing, synthesizing the information from the articles into text and tables. CM was the clinical supervisor, responsible for clinical aspects and contributing in introduction, methodology definition, and search strategies. FC was the scientific supervisor and contributed in methodology definition, article writing, discussion, and conclusion. All authors were involved in article screening and selection. All authors read, provided feedback, and approved the final article.

Author Disclosure Statement

No competing financial interests exist.

REFERENCES

1. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. The economic cost of brain disorders in Europe. *Eur J Neurol* 2012;19:155–162.
2. Yang J-X, Chen L. Economic Burden Analysis of Parkinson's Disease Patients in China. *Parkinsons Dis* 2017;2017:1–7.
3. Bovolenta TM, de Azevedo Silva SMC, Arb Saba R, Borges V, Ferraz HB, Felicio AC. Systematic review and critical analysis of cost studies associated with Parkinson's disease. *Parkinsons Dis* 2017;2017:11.
4. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. *Neurology* 2007;68:384–386.
5. Fahn S. Clinical aspects of Parkinson disease. In: Nass R, Przedborski S, eds. *Parkinson's disease: molecular and therapeutic insights from model systems*. 1st Edit. Elsevier, Inc., 2008:3–48.
6. Kadastik-Eerme L, Muldmaa M, Lilles S, Rosenthal M, Taba N, Taba P. Nonmotor features in Parkinson's disease: What are the most important associated factors? *Parkinsons Dis* 2016;2016:8.
7. Schapira AH, Chauduri RK, Jenner P. Non-motor features of Parkinson disease. *Nat Rev Neurosci* 2017;18:435–450.
8. Martinez-Martin P, Jeukens-Visser M, Lyons KE, et al. Health-related quality-of-life scales in Parkinson's disease: Critique and recommendations. *Mov Disord* 2011;26:2371–2380.
9. Dorsey ER, Vlaanderen FP, Engelen LJPG, et al. Moving Parkinson care to the home. *Mov Disord* 2016;31:1258–1262.
10. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. *Park Relat Disord* 2014;20:99–105.
11. Vu TC, Nutt JG, Holford NHG. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. *Br J Clin Pharmacol* 2012;74:267–283.
12. Holford N, Nutt J. Disease progression, drug action and Parkinson's disease: Why time cannot be ignored. *Eur J Clin Pharmacol* 2008;64:207–216.
13. Ossig C, Reichmann H. Treatment strategies in early and advanced Parkinson disease. *Neurol Clin* 2015;33:19–37.
14. Tan L, Jiang T, Tan L, Yu J-T. Toward precision medicine in neurological diseases. *Ann Transl Med* 2016;4:104.
15. Bu L, Yang K, Xiong W, et al. Toward precision medicine in Parkinson's disease. *Ann Transl Med* 2016;4:26.
16. Chen J, Mullins CD, Novak P, Thomas SB. Personalized strategies to activate and empower patients in healthcare and reduce health disparities. *Heal Educ Behav* 2016;43:25–34.
17. Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson's disease: Challenges and opportunities. *Mov Disord* 2016;31:1272–1282.
18. Wicks P, Stamford J, Grootenhuis MA, Haverman L, Ahmed S. Innovations in e-health. *Qual Life Res* 2014;23:195–203.
19. Pasluosta CF, Gassner H, Winkler J, Klucken J, Eskofier BM. An emerging era in the management of Parkinson's disease: Wearable technologies and the internet of things. *IEEE J Biomed Heal Informatics* 2015;19:1873–1881.
20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
21. Rodriguez-Martin D, Samà A, Pérez-López C, et al. Home detection of freezing of gait using Support Vector Machines through a single waist-worn triaxial accelerometer. *PLoS One* 2017;12:1–26.
22. Mazilu S, Blanke U, Dorfman M, et al. A wearable assistant for gait training for Parkinson's Disease with Freezing of Gait in Out-of-the-Lab Environments. *ACM Trans Interact Intell Syst* 2015;5:1–31.
23. Tzallas AT, Tsipouras MG, Rigas G, et al. PERFORM: A system for monitoring, assessment and management of patients with Parkinson's disease. *Sensors* 2014;14:21329–21357.
24. Stack E, King R, Janklo B, et al. Could in-home sensors surpass human observation of people with Parkinson's at high risk of falling? An ethnographic study. *Biomed Res Int* 2016;2016:1–10.
25. Cancela J, Pastorino M, Arredondo MT, Hurtado O. A telehealth system for Parkinson's disease remote monitoring: The PERFORM approach. *Conf Proc IEEE Eng Med Biol Soc* 2013;2013:7492–7495.
26. Ramsperger R, Meckler S, Heger T, et al. Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect. *Park Relat Disord* 2016;26:41–46.
27. Pérez-López C, Samà A, Rodriguez-Martin D, et al. Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer. *Artif Intell Med* 2016;67:47–56.
28. Roy SH, Cole BT, Member SSSS, et al. Resolving signal complexities for ambulatory monitoring of motor function in Parkinson's Disease. *Conf Proc IEEE Eng Med Biol Soc* 2011;2011:4832–4835.
29. Pulliam CL, Heldman DA, Brokaw EB, Mera TO, Mari ZK, Burack MA. Continuous assessment of Levodopa response in Parkinson's Disease using wearable motion sensors. *IEEE Trans Biomed Eng* 2017;9294:1.
30. Fisher JM, Hammerla NY, Ploetz T, Andras P, Rochester L, Walker RW. Unsupervised home monitoring of Parkinson's disease motor symptoms using body-worn accelerometers. *Park Relat Disord* 2016;33:44–50.
31. Das S, Amoedo B, Torre FD la, Hodges J. Detecting Parkinson's symptoms in uncontrolled home environments: A multiple instance learning approach. *Conf Proc IEEE Eng Med Biol Soc* 2012;2012:3688–3691.
32. Fisher JM, Hammerla NY, Rochester L, Andras P, Walker RW. Body-worn sensors in Parkinson's Disease: Evaluating their acceptability to patients. *Telemed e-Health* 2016;22:63–69.
33. Cancela J, Pastorino M, Arredondo MT, Nikita KS, Villagra F, Pastor MA. Feasibility study of a wearable system based on a wireless body area network for gait assessment in Parkinson's disease patients. *Sensors* 2014;14:4618–4633.
34. Cancela J, Pastorino M, Tzallas A, et al. Wearability assessment of a wearable system for Parkinson's disease remote monitoring based on a body area network of sensors. *Sensors* 2014;14:17235–17255.
35. Ferrari A, Ginis P, Nieuwboer A, Greenlaw R, Muddiman A, Chiari L. Handling gait impairments of persons with PD by means of real-time biofeedback in a daily life environment. In: Chang C, Chiari L, Cao Y, Jin H, Mokhtari M, Aloulou

ROVINI ET AL.

- H, eds. Inclusive Smart Cities and Digital Health (ICOST). Vol 9677. Cham: Springer, 2016:250–261.
36. Wagner A, Fixler N, Resheff YS. A wavelet-based approach to monitoring Parkinson's Disease symptoms. In: *Int. Conf. on Acoustics, Speech and Signal Processing (ICASSP)*. New Orleans, LA, IEEE, 2017.
 37. Monteiro A, Dubey H, Mahler L, Yang Q, Mankodiya K. Fit: A Fog computing device for speech tele-treatments. In: *Int. Conf. on Smart Computing (SMARTCOMP)*. St. Louis, MO, IEEE, 2016:10–12.
 38. Cook DJ, Schmitter-Edgecombe M, Dawadi P. Analyzing activity behavior and movement in a naturalistic environment using smart home. *J Biomed Heal Informatics* 2015;19:1882–1892.
 39. Del Din S, Godfrey A, Galna B, Lord S, Rochester L. Free-living gait characteristics in ageing and Parkinson's disease: Impact of environment and ambulatory bout length. *J Neuroeng Rehabil* 2016;13:46.
 40. Mancini M, El-Gohary M, Pearson S, et al. Continuous monitoring of turning in Parkinson's disease: Rehabilitation potential. *NeuroRehabilitation* 2015;37:3–10.
 41. Weiss A, Sharifi S, Plotnik M, van Vugt JPP, Giladi N, Hausdorff JM. Toward automated, at-home assessment of mobility among patients with Parkinson disease, using a body-worn accelerometer. *Neurorehabil Neural Repair* 2011;25:810–818.
 42. Zampieri C, Salarian A, Carlson-Kuhta P, Nutt JG, Horak FB. Assessing mobility at home in people with early Parkinson's disease using an instrumented Timed Up and Go test. *Park Relat Disord* 2011;17:277–280.
 43. El-Gohary M, McNames J, Chung K, Aboy M, Salarian A, Horak F. Continuous at-home monitoring of tremor in patients with Parkinson's Disease. *Anal Biomed Signals Images* 2010;420–424.
 44. El-Gohary M, Pearson S, McNames J, et al. Continuous monitoring of turning in patients with movement disability. *Sensors* 2014;14:356–369.
 45. Ginis P, Nieuwboer A, Dorfman M, et al. Feasibility and effects of home-based smartphone-delivered automated feedback training for gait in people with Parkinson's disease: A pilot randomized controlled trial. *Park Relat Disord* 2016;22:28–34.
 46. Rodríguez-Molinero A, Samà A, Pérez-López C, et al. Analysis of correlation between an accelerometer-based algorithm for detecting Parkinsonian gait and UPDRS subscales. *Front Neurol* 2017;8:3–8.
 47. Rahimi F, Bee C, Duval C, Boissy P, Edwards R, Jog M. Using ecological whole body kinematics to evaluate effects of medication adjustment in Parkinson disease. *J Parkinsons Dis* 2014;4:617–627.
 48. Patel S, Chen B-R, Mancinelli C, et al. Longitudinal monitoring of patients with Parkinson's disease via wearable sensor technology in the home setting. *Conf IEEE Eng Med Biol Soc* 2011;2011:1552–1555.
 49. Rahimi F, Duval C, Jog M, et al. Capturing whole-body mobility of patients with Parkinson disease using inertial motion sensors: Expected challenges and rewards. *Conf IEEE Eng Med Biol Soc* 2011;2011:5833–5838.
 50. Ferreira JJ, Godinho C, Santos AT, et al. Quantitative home-based assessment of Parkinson's symptoms: The SENSE-PARK feasibility and usability study. *BMC Neurol* 2015;15:89.
 51. Nikolova S. 28 percent purely digital players transform the mhealth market. Research2Guidance - mHealth app developer economics study 2017. <https://research2guidance.com/28-percent-digital-players-are-transforming-the-mhealth-market>. Published 2017. (last accessed December 21, 2017).
 52. Milosevic M, Jovanov E, Milenković A. Quantifying Timed-Up-and-Go Test: A smartphone implementation. In: *10th Int. Conf. on Body Sensor Networks (BSN)*. Cambridge, MA, USA, IEEE, 2013:1–6.
 53. LeMoine R, Mastroianni T, Cozza M, Coroian C, Grundfest W. Implementation of an iPhone as a wireless accelerometer for quantifying gait characteristics. *Conf IEEE Eng Med Biol Soc* 2010;2010:3847–3851.
 54. Daneault J-F, Carignan B, Codère CÉ, Sadikot AF, Duval C. Using a smart phone as a standalone platform for detection and monitoring of pathological tremors. *Front Hum Neurosci* 2013;6:357.
 55. Rigas G, Gatsios D, Fotiadis DI, et al. Tremor UPDRS Estimation in home environment. *Conf IEEE Eng Med Biol Soc* 2016;2016:3642–3645.
 56. Richer R, Groh BH, Blank P, et al. Unobtrusive real-time heart rate variability analysis for the detection of orthostatic dysregulation. In: *13th Annual Body Sensor Networks Conference (BSN)*. San Francisco, CA, USA, IEEE, 2016: 189–193.
 57. Huang Y-P, Yang W-J, Lin S-Y. An intelligent approach to identify elderly body information. In: *Int. Conf. on Automation Science and Engineering (CASE)*. Taipei, Taiwan, IEEE; 2014:824–829.
 58. Cancela J, Mascato SV, Gatsios D, et al. Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform. *Conf IEEE Eng Med Biol Soc* 2016;2016:663–666.
 59. Silva de Lima AL, Hahn T, de Vries NM, et al. Large-Scale wearable sensor deployment in Parkinson's patients: The Parkinson@Home Study Protocol. *JMIR Res Protoc* 2016;5:e172.
 60. Dzhagaryan A, Milenkovic A, Jovanov A, Milosevic A. Smart Button: A wearable system for assessing mobility in elderly. In: *17th Int. Conf. on E-Health Networking, Application and Services (HealthCom)*. Boston, MA, IEEE, 2015: 416–421.
 61. Pan D, Dhall R, Lieberman A, Petitti DB. A mobile Cloud-based Parkinson's Disease assessment system for home-based monitoring. *JMIR mHealth uHealth* 2015;3:e29.
 62. Piro NE, Baumann L, Tengler M, Piro L, Blechschmidt-Trapp R. Telemonitoring of patients with Parkinson's disease using inertia sensors. *Appl Clin Inform* 2014;5:503–511.
 63. Sahyoun A, Chehab K, Al-madani O, Aloul F, Sagahyroon A. ParkNosis: Diagnosing Parkinson's Disease using mobile phones. In: *18th Int. Conf. on E-Health Networking, Applications and Services (Healthcom)*. Munich, Germany, IEEE, 2016;1:6.
 64. Sharma V, Mankodiya K, De La Torre F, et al. SPARK: Personalized Parkinson disease interventions through synergy between a smartphone and a smartwatch. *Lecture Notes Comp Sci* 2014;8519:103–114.
 65. Tsioris KM, Gatsios D, Rigas G, et al. PD_Manager: An mHealth platform for Parkinson's disease patient management. *Healthc Technol Lett* 2017;4: 102–108.
 66. Ferrari A, Ginis P, Hardegger M, Casamassima F, Rocchi L, Chiari L. A mobile Kalman-filter based solution for the real-time estimation of spatio-temporal gait parameters. *IEEE Trans Neural Syst Rehabil Eng* 2016; 24:764–773.
 67. Chen B-R, Patel S, Buckley T, et al. A Web-based system for home monitoring of patients with Parkinson's disease using wearable sensors. *Trans Biomed Eng* 2011;58:831–836.
 68. Giansanti D, Maccioni G, Morelli S. An experience of health technology assessment in new models of care for subjects with Parkinson's disease by means of a new wearable device. *Telemed e-Health* 2008;14:467–472.
 69. Kostikis N, Arnaoutoglou M, Kotsavasiloglou C. A Smartphone-based tool for assessing Parkinsonian hand tremor. *J Biomed Heal Informatics* 2015;19: 1835–1842.
 70. Lawo M, Herzog O. Wearable computing for medical applications: Personal health system for Parkinson's disease patients. In: *8th Int. Conf. & Expo on Emerging Technologies for a Smarter World (CEWIT)*. Long Island, NY, USA: IEEE; 2011:1–5.
 71. Kim H, Lee HJ, Lee W, et al. Unconstrained detection of Freezing of Gait in Parkinson's disease patients using smartphone. *Conf IEEE Eng Med Biol Soc* 2015;2015:3751–3754.
 72. Patel S, Chen B-R, Buckley T, et al. Home monitoring of patients with Parkinson's disease via wearable technology and a web-based application. *Conf IEEE Eng Med Biol Soc* 2010;2010:4411–4414.

WEARABLE SENSORS FOR PARKINSON'S DISEASE AT HOME

73. Barroso MC, Esteves GP, Nunes TP, Silva LMG, Faria ACD, Melo PL. A telemedicine instrument for remote evaluation of tremor: Design and initial applications in fatigue and patients with Parkinson's Disease. *Biomed Eng Online* **2011**;10:14.
74. Nguyen HT, Vu CC, Phan VQ, Nguyen VD, Nguyen TD. Design system to remotely monitor patients with Parkinson's Disease. *5th Int Conf Biomed Eng Vietnam*. **2015**;46:104–105.
75. Synnott J, Chen L, Nugent CD, Moore G. WiiPD An approach for the objective home assessment of Parkinson's disease. *Conf IEEE Eng Med Biol Soc* **2011**; 2011:2388–2391.
76. Esposito D, Cavallo F. Preliminary design issues for inertial rings in Ambient Assisted Living applications. In: *Conference Record - IEEE Instrumentation and Measurement Technology Conference*. Pisa, Italy, IEEE **2015**;2015.
- AU4 77. Butt AH, Rovini E, Esposito D, Rossi G, Maremmani C, Cavallo F. Biomechanical parameter assessment for classification of Parkinson's disease on clinical scale. *Int J Distrib Sens Networks* **2017**;13.
- AU5 78. InstituteofMedicine. Challenges in Telehealth. In: *The Role of Telehealth in an Evolving Healthcare Environment: Workshop Summary*. Washington, DC: The National Academies Press; **2012**:17–29.
79. Raposo VL. Telemedicine: The legal framework (or the lack of it) in Europe. *GMS Health Technol Assess* **2016**;12: Doc03

Address correspondence to:
Filippo Cavallo, PhD
The BioRobotics Institute
Scuola Superiore Sant'Anna
Viale Rinaldo Piaggio 34
Pontedera (PI) 56025
Italy

E-mail: filippo.cavallo@santannapisa.it

Received: February 7, 2018

Revised: March 18, 2018

Accepted: March 22, 2018

AU1: Please identify (highlight or circle) all authors' surnames for accurate indexing citations.

AU2: The Publisher requests for readability that no paragraph exceeds 15 typeset lines. Please check for long paragraphs and divide where needed.

AU3: In Ref. 5, please mention the location of the publisher.

AU4: In Ref. 77, please mention the volume number or page number, whichever is missing.

AU5: In Ref. 78, please mention the editors name.

AU6: Please define PSD.

AU7: Labels a and b are in the legend of Fig. 3, but not found in figure. Please check.